Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 30, 2006. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, authorized by shareholders at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 150,000 ordinary shares of 25 pence each.
- Purchase Price: 1,482.28 pence per share.
- Total Treasury Shares Held: 191,341,678 shares following the transaction.
- Shares in Issue: 5,793,910,572 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program. The company purchased 150,000 shares on August 30, 2006, and intends to hold them in Treasury. The filing does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Key Facts for Investor Verification
- Verify the total cost of the 150,000 share repurchase based on the disclosed price of 1,482.28 pence per share.
- Confirm the updated total number of shares in issue (5,793,910,572) and the cumulative Treasury share count (191,341,678).
- Note that this filing is a notification of a specific transaction and does not contain quarterly or annual financial results.